Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rx Industry "Jumpstarts" Anti-Counterfeit Technology Through RFID Coalition

This article was originally published in The Pink Sheet Daily

Executive Summary

The coalition comprises wholesalers, manufacturers and retailers assessing the business value of using an electronic product code for drugs. The group communicates frequently with FDA and is conducting tests of radio-frequency identification technology for the agency.

You may also be interested in...



Radio Frequency ID Could Be Implemented On At Least Limited Scale By 2007, Group Says

Results from a pilot study released by the “Jumpstart” anti-counterfeit coalition indicate that RFID technology could satisfy regulatory and retailer requirements. Pfizer says global standards need to be developed before widespread adoption will occur.

Radio Frequency ID Could Be Implemented On At Least Limited Scale By 2007, Group Says

Results from a pilot study released by the “Jumpstart” anti-counterfeit coalition indicate that RFID technology could satisfy regulatory and retailer requirements. Pfizer says global standards need to be developed before widespread adoption will occur.

Pfizer Hopes To Deter Viagra Counterfeits With Color-Shifting Labels

Color-shifting labels will be introduced this week, Pfizer’s McPhillips tells Healthcare Distribution Management Association conference in Las Vegas. The technology may be expanded to other products.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS059607

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel